Safety and factors of efficacy of hypotensive therapy in pediatric uveitic glaucoma
Accept poster if oral is not possible ?
Yes
Purpose
To analyze safety and factors of efficacy of hypotensive therapy in pediatric uveitic glaucoma (UG).
Methods
178 eyes of 104 children aged from 2 to 15 years (mean 8.7) with open angle or combined with peripheral anterior synechiae forms of UG were treated with topical beta-blockers, carbonic-anhydrase inhibitors, brimonidine and in remission of uveitis – with prostaglandin analogs. Anterior uveitis - 112 eyes, intermediate - 49, posterior - 3, panuveitis - 14; phakic - 118, pseudophakic - 34, aphakic - 26; remission of uveitis - in 116 eyes.
Results
Duration of IOP compensation before primary hypotensive operation varied from 1 to 86 months (median 11). Factors, associated with failure, were anterior uveitis (vs. intermediate) (p=0.03), pseudophakic or aphakic eye (vs. phakic) (p=0.03, p=0.001 respectively), active uveitis vs. remission (tendency p=0.13). Frequency of topical steroid (3 and more drops a day vs. less than 3) had no influence on treatment efficacy. Local or systemic side effects were detected in 14.3% cases and included bradycardie 1.9%, bronchial asthma exacerbation 1.9% (beta-blockers), drowsiness 3.9% (brimonidine), burning and redness 4.8% (prostaglandin analogs).
Conclusion
Conventional hypotensive therapy is safe (with best profile for carbonic-anhydrase inhibitors), especially effective in intermediate uveitis, in phakic eyes and in remission of uveitis, and should be considered as first step in treatment of open angle or combined forms of pediatric UG.
Conflict of interest
No
Author 1
Last name
DENISOVA
Initials of first name(s)
E.
Department
Helmholtz Research Institute of Eye Diseases
City
Moscow
Country
Russian Federation
Author 2
Last name
Katargina
Initials of first name(s)
L.
Department
Helmholtz Research Institute of Eye Diseases
City
Moscow
Country
Russian Federation
Author 3
Last name
Ibaid
Initials of first name(s)
B.N.
Department
Helmholtz Research Institute of Eye Diseases
City
Moscow
Country
Russian Federation
This website uses cookies to ensure you get the best experience on our website.
Learn more